



Where can patients and healthcare professionals find information on shortages?

Inga Abed

You can't fix what you can't see



Patients and **healthcare professionals** need timely **information** about medicine shortages



Only well-informed patients and healthcare professionals can **proactively seek solutions**



Where to find information on shortages?



Healthcare professionals

- Healthcare professional organisations
- National medicine regulator
- EMA website
 - shortage catalogue entry
 - letters (also sent directly)

Patients

- Doctor / pharmacist
- Patient organisations
- Media
- National medicine regulator
- EMA website
 - shortage catalogue entry



EMA shortages catalogue

Public information on medicine shortages



The European Medicines Agency (EMA) publishes information on medicine shortages that affect or are likely to affect more than one European Union (EU) country, where it has assessed the shortage and provided recommendations to patients and healthcare professionals.

Human Regulatory and procedural guidance Medicine shortages Medicines

Page contents

[EMA shortages catalogue](#)

[Communication to healthcare professionals](#)

[National registers of shortages](#)

[Related content](#)

[External links](#)

EMA also publishes information on **critical shortages** monitored at EU [Contact \(SPOC\) Working Party](#).

EMA monitors **critical medicine shortages** that might lead to a crisis working with the EU Member States and European Commission. For more information, see:

- [Crisis preparedness and management](#)
- [Executive Steering Group on Shortages and Safety of Medicinal Products](#)

EMA's responsibilities in this area stem from [Regulation on EMA's Reinforced Role](#).

The Agency's shortages catalogue below contains information on supply shortages.




The minutes of the Medicine Shortages Single Point of Contact (SPOC) Working Party are available on the [EMA website](#).

- [Medicines Shortages SPOC Working Party meetings](#)

National registers of shortages

The table below contains the national registers of shortages for **human** and **veterinary medicines**.

Please note that the information in these national registers may not be available in English.

EU Member State	National register
 Austria	<ul style="list-style-type: none">• Human and veterinary medicines share the same online register: medicineshortage.basg.gv.at
 Belgium	<ul style="list-style-type: none">• Human medicines: www.famhp.be• Veterinary medicines: genesmiddelendatabank.fagg-afmps.be
 Bulgaria	<ul style="list-style-type: none">• Human medicines: www.bda.bg• Veterinary medicines: no online register available

Mimpara - supply shortage

cinacalcet

Shortage

Human

Share

Ongoing



Recommendations for healthcare professionals

- The company that markets Mimpara in the EU has decided to stop marketing all strengths of Mimpara tablets and granules in capsules for opening due to commercial reasons;
- The date of discontinuation varies by Member State, as mentioned above;
- Before initiating treatment with Mimpara, check with your [national competent authority](#) in case they have issued national recommendations;
- Switch existing patients to an alternative treatment, taking into account the following information:
- different [generic versions of cinacalcet tablets](#) are available; however, there is [no generic of cinacalcet granules in capsules for opening](#);
- Etelcalcetide (Parsabiv) is authorised for adults with secondary hyperparathyroidism and chronic kidney disease on haemodialysis. Etelcalcetide should not be initiated in patients until 7 days after the last dose of cinacalcet and the corrected serum calcium is at or above the lower limit of the normal range;
- treatment alternatives may differ across Member States.
- A [medicine shortage communication \(MSC\)](#) has been sent to healthcare professionals in affected Member States.
- For additional information, consult your country's shortage register or contact your [national competent authority](#).

Page contents

Shortage information

Key facts

Key dates

Related medicine information

Related content

Shortage information

There is a shortage of Mimpara in some EU Member States.

Mimpara is a medicine used to treat:

- secondary hyperparathyroidism (overactive parathyroid glands) in adults and children aged 3 years and older with serious kidney disease who need dialysis (to clear their blood of waste products);
- hypercalcaemia (high blood calcium levels) in adults with cancer of the parathyroid glands, or with primary hyperparathyroidism when the parathyroid glands cannot be removed.

Mimpara is available as tablets and as granules in capsules for opening. The tablets can be used by adults and children who need doses of 30 mg or more and are able to swallow tablets. The granules in capsules for opening are used in younger children and in patients with difficulty swallowing.

For further information on the use of the medicine, please refer to the medicine's overview page.

Reason for shortage

The company that markets Mimpara in the EU has decided to stop marketing all strengths of Mimpara tablets and granules in capsules for opening in the EU due to commercial reasons. This decision is not related to a quality or safety issue. The timeline for the discontinuation varies between Member States and discontinuation has either taken effect or will take effect between March and September 2025.

Member States affected

For tablets:

- Member States where discontinuation occurred in June 2024: Austria, Croatia, Cyprus, Germany, Ireland, Italy, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Spain and France;
- Member States where discontinuation is planned in March 2025: Greece and Hungary;
- Member States where discontinuation is planned in September 2025: Belgium and Slovenia.

For granules in capsules for opening:

- Member States where discontinuation is planned in March 2025: Croatia, Czechia, Germany, Ireland, Netherlands and Portugal;
- Member State where discontinuation is planned in September 2025: France;
- Member States where discontinuation will occur either when available supplies are depleted or in September 2025, whichever comes first: Slovenia and Spain.

For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the [national competent authority](#).

Monitoring of shortage

Recommendations for patients and carers

- The company that markets Mimpara in the EU has decided to stop marketing all strengths of Mimpara tablets and granules in capsules for opening due to commercial reasons;
- if you or your child are being treated with Mimpara, your doctor will recommend a different treatment;
- [contact your pharmacy or doctor well before your or your child's supply of the medicine runs out](#);
- If you have any questions, speak to your or your child's doctor or pharmacist.
- For additional information, consult your country's shortage register or contact your [national competent authority](#).


Key facts

Medicines affected	Mimpara
Supply shortage status	Ongoing
International non-proprietary name (INN) or common name	cinacalcet
Therapeutic area (MESH)	<ul style="list-style-type: none">• Hypercalcaemia• Parathyroid Neoplasms• Hyperparathyroidism
Pharmaceutical forms affected	<ul style="list-style-type: none">• Tablet• Granules in capsule
Strengths affected	<ul style="list-style-type: none">• 30, 60, 90mg (tablets)• 1, 2.5, 5mg (granules in capsule)
Availability of alternatives	Yes


Actively disseminated to organisations and through newsletter



Where do healthcare professionals turn to for information on shortages?




Where do patients turn to for information on shortages?



FIGHTING MEDICINE
SHORTAGES

It takes a team.



Conclusion

- **Timely** and **transparent communication** is key for patients and healthcare professionals to proactively seek solutions and mitigate impacts on patient care
- **Regulatory bodies** like EMA play a crucial role in issuing communications
- **Stay informed**: use shortage catalogues from EMA or your national medicines agency for reliable medicine shortage updates

